Published in J Clin Invest on October 01, 2010
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med (2012) 1.82
A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4. Nat Immunol (2014) 1.54
IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med (2012) 1.48
The TIR Homologue Lies near Resistance Genes in Staphylococcus aureus, Coupling Modulation of Virulence and Antimicrobial Susceptibility. PLoS Pathog (2017) 1.39
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun (2012) 1.18
TLR4 protein contributes to cigarette smoke-induced matrix metalloproteinase-1 (MMP-1) expression in chronic obstructive pulmonary disease. J Biol Chem (2011) 1.18
Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol (2011) 1.10
NF-κB and cancer: a paradigm of Yin-Yang. Am J Cancer Res (2010) 1.08
The application of Toll like receptors for cancer therapy. Int J Biol Sci (2010) 1.01
Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A (2012) 0.95
Sp1 transcription factor interaction with accumulated prelamin a impairs adipose lineage differentiation in human mesenchymal stem cells: essential role of sp1 in the integrity of lipid vesicles. Stem Cells Transl Med (2012) 0.94
Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol (2011) 0.93
MyD88 and its divergent toll in carcinogenesis. Trends Immunol (2013) 0.88
Low concentration of S100A8/9 promotes angiogenesis-related activity of vascular endothelial cells: bridges among inflammation, angiogenesis, and tumorigenesis? Mediators Inflamm (2012) 0.88
MyD88 in DNA repair and cancer cell resistance to genotoxic drugs. J Natl Cancer Inst (2013) 0.87
Oxidation as "the stress of life". Aging (Albany NY) (2011) 0.87
Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis. Cell Commun Signal (2015) 0.87
Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med (2012) 0.86
Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, barrett's esophagus, dysplasia and adenocarcinoma. Oncoimmunology (2016) 0.85
MyD88 is involved in myeloid as well as lymphoid hematopoiesis independent of the presence of a pathogen. Am J Blood Res (2013) 0.83
Myeloid differentiation primary response gene 88-leukotriene B4 receptor 2 cascade mediates lipopolysaccharide-potentiated invasiveness of breast cancer cells. Oncotarget (2015) 0.82
Stem cell niche dynamics: from homeostasis to carcinogenesis. Stem Cells Int (2012) 0.81
A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol (2013) 0.79
Enhanced myeloid differentiation factor 88 promotes tumor metastasis via induction of epithelial-mesenchymal transition in human hepatocellular carcinoma. Cell Death Dis (2014) 0.78
LPS Up-Regulates ICAM-1 Expression in Breast Cancer Cells by Stimulating a MyD88-BLT2-ERK-Linked Cascade, Which Promotes Adhesion to Monocytes. Mol Cells (2015) 0.77
Repressing DNA repair to enhance chemotherapy: targeting MyD88 in colon cancer. J Natl Cancer Inst (2013) 0.76
The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer. Oncogene (2016) 0.75
ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2. Oncotarget (2016) 0.75
Pattern recognition receptors and DNA repair: starting to put a jigsaw puzzle together. Front Immunol (2014) 0.75
A Multifaceted Role for Myd88-Dependent Signaling in Progression of Murine Mammary Carcinoma. Breast Cancer (Auckl) (2016) 0.75
A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men. PLoS One (2016) 0.75
Downregulation of adaptor protein MyD88 compromises the angiogenic potential of B16 murine melanoma. PLoS One (2017) 0.75
Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 12.63
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 5.54
Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem (2007) 4.56
Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci (2000) 3.67
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol (2006) 3.44
Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med (2003) 3.24
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
At the crossroads of inflammation and cancer. Cell (2004) 2.96
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci U S A (1986) 1.83
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg (2004) 1.25
Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem (2009) 1.17
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer (2003) 1.11
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res (2006) 4.00
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
TLR3 can directly trigger apoptosis in human cancer cells. J Immunol (2006) 2.79
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett (2006) 2.37
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res (2005) 2.24
Genetics of lung-cancer susceptibility. Lancet Oncol (2010) 2.24
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer (2006) 2.17
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol (2005) 2.05
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat (2002) 1.99
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
On the origin of G --> T transversions in lung cancer. Mutat Res (2003) 1.89
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol (2011) 1.85
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol (2009) 1.82
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. Gut (2010) 1.71
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology (2004) 1.69
Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol (2006) 1.68
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol (2007) 1.64
Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett (2011) 1.62
Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol (2002) 1.55
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol (2006) 1.55
Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol (2002) 1.53
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene (2005) 1.49
Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging. Protein Sci (2005) 1.49
Biospecimen reporting for improved study quality (BRISQ). J Proteome Res (2011) 1.48
Massively regulated genes: the example of TP53. J Pathol (2010) 1.46
Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol Cell Biol (2005) 1.45
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.44
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett (2008) 1.44
In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology (2009) 1.43
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J (2002) 1.42
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res (2007) 1.41
Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol (2013) 1.40
International efforts to develop biospecimen best practices. Cancer Epidemiol Biomarkers Prev (2010) 1.38
Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer (2011) 1.36
Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer (2010) 1.35
G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis (2010) 1.34
Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One (2007) 1.34
Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32
Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat (2010) 1.32
Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol (2006) 1.29
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res (2007) 1.27
Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol (2010) 1.26
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep (2006) 1.24
Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett (2009) 1.22
Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect (2008) 1.22
Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer (2004) 1.21
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol (2010) 1.17
Chemokine receptor CCR2 but not CCR5 or CCR6 mediates the increase in pulmonary dendritic cells during allergic airway inflammation. J Immunol (2007) 1.17
TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res (2006) 1.16
Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A (2002) 1.16
DNA adducts and lung cancer risk: a prospective study. Cancer Res (2005) 1.14
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res (2011) 1.14
Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene (2005) 1.13
Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. Cancer Res (2010) 1.13
Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol (2013) 1.12
Biospecimen Reporting for Improved Study Quality. Biopreserv Biobank (2011) 1.12
Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev (2005) 1.12
Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One (2011) 1.11
TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. Mutagenesis (2004) 1.11
Network of dendritic cells within the muscular layer of the mouse intestine. Proc Natl Acad Sci U S A (2005) 1.10
High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology (2006) 1.09
Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol (2011) 1.09
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett (2009) 1.09
Lipoteichoic acid increases TLR and functional chemokine expression while reducing dentin formation in in vitro differentiated human odontoblasts. J Immunol (2006) 1.07
Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res (2004) 1.07
Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer (2007) 1.06
MHC class II compartments in human dendritic cells undergo profound structural changes upon activation. Traffic (2002) 1.06
CD208/dendritic cell-lysosomal associated membrane protein is a marker of normal and transformed type II pneumocytes. Am J Pathol (2004) 1.06
Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol (2004) 1.06
Biobanking in a fast moving world: an international perspective. J Natl Cancer Inst Monogr (2011) 1.06
Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int (2010) 1.05
p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene (2004) 1.04
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Human tissue biobanks as instruments for drug discovery and development: impact on personalized medicine. Biomark Med (2010) 1.02
Tumor necrosis factor (TNF)-α, soluble TNF receptors and endometrial cancer risk: the EPIC study. Int J Cancer (2011) 1.01
Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of Ras, protein kinase C, and protein kinase A in neuronal cells. J Biol Chem (2002) 1.01